Blinatumomab and ponatinib for newly diagnosed Philadelphia chromosome-positive ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of Philadelphia chromosome-positive (Ph+) or BCR-ABL1 positive acute lymphoblastic leukemia (ALL) that is also CD19 positive.
- You must have at least 5% leukemic blasts in your bone marrow.
- You must not have had any prior induction chemotherapy, though a short course of steroids or hydroxyurea may have been given.
- You must be in adequate overall health, with acceptable liver, kidney, pancreas, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests two drugs—blinatumomab (an immune therapy) and olverembatinib (a targeted pill)—for people with a specific type of ALL that has the Ph chromosome or BCR::ABL1 gene. It aims to see if this combination works well in controlling the disease.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
Hear when a new Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.